Immunohistochemical analysis of metastatic neoplasms of the central nervous system

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 10, 2006, Pages 935-944

  Becher, Mark W ^a   Abel, Ty W ^a   Thompson, Reid C ^a   Weaver, Kyle D ^a   Davis, Larry E ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

Brain metastases; Intermediate filaments; Tumor markers; Unknown primary

Indexed keywords

ANTIBODY; CYTOKERATIN; REAGENT; TUMOR MARKER;

ANTIBODY SPECIFICITY; BRAIN METASTASIS; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM TUMOR; COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT; NEUROPATHOLOGY; NEUROSURGERY; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

ALGORITHMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PATHOLOGY, SURGICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 33749494473     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000235124.82805.2b     Document Type: Review

References (57)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics 2004. CA Cancer J Clin 2004;54:8-29
2. Vecht CJ. Clinical management of brain metastasis. J Neurol 1998;245:127-31
3. Posner JB. Neurologic Complications of Cancer. Philadelphia: FA Davis, 1995
4. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003;21:1-23
5. Polyzoidis KS, Miliaras G, Pavlidis N. Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma. Cancer Treat Rev 2005;31:247-55
6. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; Incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-13
7. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005
8. Burger PC, Scheithauer BW, Vogel FS. Surgical Pathology of the Nervous System and Its Coverings. Philadelphia: Churchill Livingstone, 2002
9. Sills AK. Current treatment approaches to surgery for brain metastases. Neurosurgery 2005;57:S4:24-32
10. Modha A, Shepard SR, Gutin PH. Surgery of brain metastases - is there still a place for it? J Neurooncol 2005;75:21-29
11. Sheehan J, Niranjan A, Flickinger JC, et al. The expanding role of neurosurgeons in the management of brain metastases. Surg Neurol 2004;62:32-40
12. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500
13. Farag SS, Green MD, Morstyn G, et al. Delay by internists in obtaining diagnostic biopsies in patients with suspected cancer. Ann Intern Med 1992;116:473-78
14. Raab SS. Cost-effectiveness of immunohistochemistry. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone, 2002:45-56
15. Nathoo N, Chahlavi A, Barnett GH, et al. Pathobiology of brain metastases. J Clin Pathol 2005;58:237-42
16. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72
17. Dabbs DJ. Immunohistology of metastatic carcinoma of unknown primary. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone, 2006:180-226
18. Quan AL, Videtic GM, Suh JH. Brain metastases in small cell lung cancer. Oncology (Williston Park) 2004;18:961-72
19. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-72
20. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-19
21. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin. In: Santa Cruz DJ, ed. Seminars in Diagnostic Pathology: Immunohistochemistry in Tumor Diagnosis. Philadelphia: WB Saunders, 2000:184-93
22. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: An immunohistochemical approach. Hum Pathol 1997;28:938-43
23. Drlicek M, Bodenteich A, Urbanits S, et al. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004;200:727-34
24. Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: A clinico-pathologic study. J Neurooncol 2000;50:265-73
25. Cerilli LA, Wick MR. Immunohistology of soft tissue and osseous neoplasms. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone, 2006:65-120
26. Okamura N, Yoshida M, Shibuya A, et al. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: Comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int 2005;55:724-31
27. Chen PC, Chen CK, Nicastri AD, et al. Myoepithelial carcinoma of the breast with distant metastasis and accompanied by adenomyoepitheliomas. Histopathology 1994;24:543-48
28. Alos L, Cardesa A, Bombi JA, et al. Myoepithelial tumors of salivary glands: A clinicopathologic, immunohistochemical, ultrastructural, and flow-cytometric study. Semin Diagn Pathol 1996;13:138-47
29. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24
30. Oh D, Prayson RA. Evaluation of epithelial and keratin markers in glioblastoma multiforme: An immunohistochemical study. Arch Pathol Lab Med 1999;123:917-20
31. Coons SW, Estrada SI, Gamez R, et al. Cytokeratin CK 7 and CK 20 expression in pituitary adenomas. Endocr Pathol 2005;16:201-10
32. Kawano N, Ohba Y, Nagashima K. Eosinophilic inclusions in ependymoma represent microlumina: A light and electron microscopic study. Acta Neuropathol (Berl) 2000;99:214-18
33. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-73
34. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-19
35. Srodon M, Westra WH. Immunohistochemical staining for thyroid transcription factor-1: A helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol 2002;33:642-45
36. Lazzaro D, Price M, de Felice M, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 1991;113:1093-104
37. Lee BJ, Cho GJ, Norgren RB Jr, et al. TTF-1, a homeodomain gene required for diencephalic morphogenesis, is postnatally expressed in the neuroendocrine brain in a developmentally regulated and cell-specific fashion. Mol Cell Neurosci 2001;17:107-26
38. Son YJ, Hur MK, Ryu BJ, et al. TTF-1, a homeodomain-containing transcription factor, participates in the control of body fluid homeostasis by regulating angiotensinogen gene transcription in the rat subfornical organ. J Biol Chem 2003;278:27043-52
39. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev 1996;10:60-69
40. Bohinski RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1. J Neurooncol 1998;40:227-31
41. Mantovani G, Corbetta S, Romoli R, et al. Absence of thyroid transcription factor-1 expression in human parathyroid and pituitary glands. Mol Cell Endocrinol 2001;182:13-17
42. Prok AL, Prayson RA. Thyroid transcription factor-1 staining is useful in identifying brain metastases of pulmonary origin. Ann Diagn Pathol 2006;10:67-71
43. Zamecnik J, Chanova M, Kodet R. Expression of thyroid transcription factor 1 in primary brain tumours. J Clin Pathol 2004;57:1111-13
44. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10
45. Witek ME, Nielsen K, Walters R, et al. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 2005;11:8549-56
46. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: An immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-19
47. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: Potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005;29:747-54
48. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: The use of the monoclonal antibody Frenal cell carcinoma marker.' Am J Surg Pathol 2001;25:1485-92
49. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000;24:203-10
50. Pan CC, Chen PC, Ho DM. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: An immunohistochemical analysis of 328 cases. Histopathology 2004;45:452-59
51. Dabbs DJ. Immunohistology of the breast. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone, 2006: 669-745
52. Ludwin SK, Kosek JC, Eng LF. The topographical distribution of S-100 and GFA proteins in the adult rat brain: An immunohistochemical study using horseradish peroxidase-labelled antibodies. J Comp Neurol 1976;165:197-207
53. Wick MR. Immunohistology of melanocytic neoplasms. In: Dabbs DJ, ed. Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone, 2006:162-79
54. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-19
55. Zimmer C, Gottschalk J, Goebel S, et al. Melanoma-associated antigens in tumours of the nervous system: An immunohistochemical study with the monoclonal antibody HMB-45. Virchows Arch A Pathol Anat Histopathol 1992;420:121-26
56. Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology 2000;36:387-402
57. Takeda K, Yasumoto K, Takada R, et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem 2000;275:14013-16